Close Menu

NEW YORK – Cambridge, Massachusetts-based Agios Pharmaceuticals on Friday announced that it had withdrawn its marketing application with the European Medicines Agency for ivosidenib (Tibsovo) for the treatment of patients with IDH1-mutated relapsed or refractory acute myeloid leukemia.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.